250 related articles for article (PubMed ID: 28330901)
21. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
22. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
Fransolet G; Ehx G; Somja J; Delens L; Hannon M; Muller J; Dubois S; Drion P; Caers J; Humblet-Baron S; Delvenne P; Beguin Y; Conteduca G; Baron F
J Hematol Oncol; 2016 Jul; 9(1):53. PubMed ID: 27377819
[TBL] [Abstract][Full Text] [Related]
23. Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation.
Vela-Ojeda J; Montiel-Cervantes L; Granados-Lara P; Reyes-Maldonado E; García-Latorre E; Garcia-Chavez J; Majluf-Cruz A; Mayani H; Borbolla-Escoboza JR; Esparza MG
Stem Cells Dev; 2010 Mar; 19(3):333-40. PubMed ID: 19919293
[TBL] [Abstract][Full Text] [Related]
24. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
25. Host CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease.
Kim J; Kim W; Kim HJ; Park S; Kim HA; Jung D; Choi HJ; Park SJ; Mittler RS; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2012 Jan; 18(1):44-54. PubMed ID: 21958951
[TBL] [Abstract][Full Text] [Related]
26. DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.
Nishikii H; Kim BS; Yokoyama Y; Chen Y; Baker J; Pierini A; Alvarez M; Mavers M; Maas-Bauer K; Pan Y; Chiba S; Negrin RS
Blood; 2016 Dec; 128(24):2846-2858. PubMed ID: 27760760
[TBL] [Abstract][Full Text] [Related]
27. Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.
Belle L; Agle K; Zhou V; Yin-Yuan C; Komorowski R; Eastwood D; Logan B; Sun J; Ghilardi N; Cua D; Williams CB; Gaignage M; Marillier R; van Snick J; Drobyski WR
Blood; 2016 Oct; 128(16):2068-2082. PubMed ID: 27488350
[TBL] [Abstract][Full Text] [Related]
28. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
29. [Difference between FOXP3 gene expressions in donor grafts with or without acute graft-versus-host disease].
Wang ZD; Feng SZ; Zhou SY; Wang M; Zhou Z; Zhai WJ; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1215-20. PubMed ID: 17204197
[TBL] [Abstract][Full Text] [Related]
30. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
[TBL] [Abstract][Full Text] [Related]
31. Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.
Vaeth M; Bäuerlein CA; Pusch T; Findeis J; Chopra M; Mottok A; Rosenwald A; Beilhack A; Berberich-Siebelt F
Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1125-30. PubMed ID: 25583478
[TBL] [Abstract][Full Text] [Related]
32. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation.
Lim DG; Koo SK; Park YH; Kim Y; Kim HM; Park CS; Kim SC; Han DJ
Transplantation; 2010 Apr; 89(8):928-36. PubMed ID: 20305583
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
[TBL] [Abstract][Full Text] [Related]
34. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease.
Biagi E; Di Biaso I; Leoni V; Gaipa G; Rossi V; Bugarin C; Renoldi G; Parma M; Balduzzi A; Perseghin P; Biondi A
Transplantation; 2007 Jul; 84(1):31-9. PubMed ID: 17627234
[TBL] [Abstract][Full Text] [Related]
35. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells.
Chen X; Bäumel M; Männel DN; Howard OM; Oppenheim JJ
J Immunol; 2007 Jul; 179(1):154-61. PubMed ID: 17579033
[TBL] [Abstract][Full Text] [Related]
36. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
Front Immunol; 2022; 13():796349. PubMed ID: 35242129
[TBL] [Abstract][Full Text] [Related]
37. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation.
Bucher C; Koch L; Vogtenhuber C; Goren E; Munger M; Panoskaltsis-Mortari A; Sivakumar P; Blazar BR
Blood; 2009 Dec; 114(26):5375-84. PubMed ID: 19843883
[TBL] [Abstract][Full Text] [Related]
38. Effect of rapamycin and interleukin-2 on regulatory CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation.
Wang X; Wang W; Xu J; Le Q
Transplant Proc; 2013 Mar; 45(2):528-37. PubMed ID: 23267787
[TBL] [Abstract][Full Text] [Related]
39. A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management.
Avivi I; Stroopinsky D; Rowe JM; Katz T
Transpl Immunol; 2013 Jan; 28(1):57-61. PubMed ID: 23196257
[TBL] [Abstract][Full Text] [Related]
40. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]